Of these, 590 patients (39.8%) had luminal B breast cancer while the remaining 891 patients (60.2%), who had triple-negative, HER2-enriched, or luminal A breast cancer, were excluded from the study. The gene discussed is ERBB2; the disease is breast carcinoma.